Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children's Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis

Eric L Simpson, Marjolein de Bruin-Weller, Laurent Eckert, Diane Whalley, Isabelle Guillemin, Matthew Reaney, Zhen Chen, Lauren Nelson, Shanshan Qin, Ashish Bansal, Abhijit Gadkari, Eric L Simpson, Marjolein de Bruin-Weller, Laurent Eckert, Diane Whalley, Isabelle Guillemin, Matthew Reaney, Zhen Chen, Lauren Nelson, Shanshan Qin, Ashish Bansal, Abhijit Gadkari

Abstract

Introduction: The Patient-Oriented Eczema Measure (POEM) assesses patient-reported frequency of atopic dermatitis (AD) symptoms, while the Children's Dermatology Life Quality Index (CDLQI) measures the impact of skin disease on health-related quality of life (HRQoL) in children. There is currently no threshold for clinically meaningful within-person change in POEM or CDLQI scores in adolescents. Here we empirically derive within-person thresholds of meaningful within-person change in POEM and CDLQI scores in adolescents with moderate-to-severe AD.

Methods: Data were used from a phase 3, randomized, double-blind, placebo-controlled trial of dupilumab in adolescents (aged ≥ 12 to < 18 years) with moderate-to-severe AD. Anchor-based methods were employed using the mean change in POEM and CDLQI scores from baseline to week 16 linked with a 1-point improvement in Patient Global Assessment of Disease (PGAD), a score of "a little better" on the Patient Global Assessment of Treatment effect (PGAT), a 50-74% improvement from baseline in the Eczema Area and Severity Index (EASI-50-74), and a 1-point improvement in Investigator's Global Assessment (IGA) score.

Results: A mean change of - 7.8 and - 5.6 in the POEM score was associated with PGAD and PGAT anchors, respectively. EASI-50-74 was associated with a mean change in POEM score of - 8.2, while the IGA anchor was associated with a mean change of - 7.9 in POEM score. The mean changes in CDLQI score associated with PGAD and PGAT anchors were - 6.4 and - 6.6, respectively, while CDLQI mean scores changed by - 8.3 and - 8.0 for the EASI and IGA anchors, respectively.

Conclusion: In adolescents (aged ≥ 12 to < 18 years) with moderate-to-severe AD, a within-person change of 6-8 points in POEM and CDLQI scores, independently, can be considered a reasonable responder threshold for clinically meaningful change in each of the two scales, respectively.

Trial registration: ClinicalTrials.gov Identifier: NCT03054428.

Funding: Sanofi and Regeneron Pharmaceuticals, Inc.

Keywords: Adolescents; Atopic dermatitis; CDLQI; Dupilumab; POEM; Quality of life; Responder threshold; Validation.

References

    1. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140(12):1513–1519. doi: 10.1001/archderm.140.12.1513.
    1. Gerbens LAA, Prinsen CAC, Charmers JR, et al. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2017;72(1):146–163. doi: 10.1111/all.12959.
    1. Chalmers JR, Simpson E, Apfelbacher CJ, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) Br J Dermatol. 2016;175(1):69–79. doi: 10.1111/bjd.14773.
    1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
    1. Lewis-Jones MS, Finlay AY. The Children’s Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–949. doi: 10.1111/j.1365-2133.1995.tb16953.x.
    1. Salek MS, Jung S, Brincat-Ruffini LA, et al. Clinical experience and psychometric properties of the children’s dermatology life quality index (CDLQI), 1995–2012. Br J Dermatol. 2013;169(4):734–759. doi: 10.1111/bjd.12437.
    1. Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. doi: 10.1111/j.1398-9995.2011.02719.x.
    1. Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27–33. doi: 10.1159/000365390.
    1. Simpson EL, Paller AS, Siegfried EC, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. In: Poster presented at the 27th European Academy of Dermatology and Venereology congress; Paris, France; September 12–16, 2018.
    1. US Food and Drug Administration. (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. . Accessed April 2019.
    1. Gaunt DM, Metcalfe C, Ridd M. The patient-oriented eczema measure in young children: responsiveness and minimal clinically important difference. Allergy. 2016;71(11):1620–1625. doi: 10.1111/all.12942.
    1. Howells L, Ratib S, Chalmers JR, et al. How should minimally important change scores for the patient-oriented eczema measure be interpreted? A validation using varied methods. Br J Dermatol. 2018;178(5):1135–1142. doi: 10.1111/bjd.16367.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe